^
    Back
    Association details:
    Biomarker:TP53 mutation
    Cancer:Ovarian Cancer
    Drug:ganetespib (ADX-1612) (HSP90 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer

    Excerpt:
    ...- Availability of archival ovarian cancer tissue for central histopathological review and p53 mutational analysis...
    Trial ID:
    GANNET53
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESGO 2019
    Title:

    TP53 mutations in cell-free DNA as early markers of therapeutic response in platinum-resistant relapsed ovarian cancer (PROC): a prospective translational analysis of the phase II GANNET53 clinical trial

    Published date:
    11/03/2019
    Excerpt:
    Detection of ctDNA at C1D1 (HR 2.3; 95%CI:1.4-3.9), C1D2 (HR 2.2; 95%CI:1.3-3.9) and C2D1 (HR 2.8; 95%CI:1.6-4.9) predicted a worse overall survival. A subgroup of patients for whom TP53 ctDNA was undetectable at C2D1 or C3D1 (14/64) had a high overall response rate of 64.2%.